The stock of Cybin Inc (AMEX:CYBN) last traded at $0.46, down -2.54% from the previous session.
Data from the available sources indicates that Cybin Inc (AMEX:CYBN) is covered by 4 analysts. The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $10.00 and a low of $3.00, we find $4.75. Given the previous closing price of $0.47, this indicates a potential upside of 910.64 percent. CYBN stock price is now -8.38% away from the 50-day moving average and 15.18% away from the 200-day moving average. The market capitalization of the company currently stands at $111.59M.
In total, 0 analysts have assigned it a hold rating, and 4 have given it a buy rating. Brokers who have rated the stock have averaged $5.63 as their price target over the next twelve months.
A total of 24.40% of the company’s stock is owned by insiders.
With an opening price of $0.4710 on Tuesday morning, Cybin Inc (AMEX: CYBN) set off the trading day. During the past 12 months, Cybin Inc has had a low of $0.21 and a high of $0.74. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 2.61, and a quick ratio of 2.61. The fifty day moving average price for CYBN is $0.5020 and a two-hundred day moving average price translates $0.3994 for the stock.
The latest earnings results from Cybin Inc (AMEX: CYBN) was released for Jun, 2023.
Cybin Inc(CYBN) Company Profile
Cybin Inc., a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company’s development pipeline includes CYB003, a deuterated psilocybin analog, which is in Phase 1/2a clinical trial to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine, which is in Phase 1 clinical trial for treating generalized anxiety disorders; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation. It has also developed EMBARK, a psychological support model that integrates clinical approaches to promote supportive healing with psychedelic medicine. The company is headquartered in Toronto, Canada.
